Financial Performance - Net revenue increased by 19.0% to $14.7 million in Q1 FY 2025, up from $12.3 million in Q1 FY 2024[2] - Gross margin improved to 78.3% of net revenues, compared to 77.1% in the same quarter last year[2] - Operating income rose to $1.9 million, representing 13.2% of revenue, compared to $0.1 million or 1.2% of revenue in Q1 FY 2024[2] - Net income was $1.5 million, or $0.16 per diluted share, compared to $0.2 million, or $0.02 per diluted share in Q1 FY 2024[2] - Net income for the three months ended September 30, 2024, increased to $1,474,000 compared to $155,000 for the same period in 2023, representing a significant growth[17] Revenue Sources - Revenue from the direct homecare business increased by 18.5% to $13.2 million, driven by more referrals and an increase in direct sales representatives[5] - The annualized homecare revenue per weighted average direct sales representative was $985,000, at the higher end of the target range of $900,000 to $1,000,000[5] Expenses and Cash Flow - Selling, general and administrative expenses were $9.4 million, an increase of 2.6% compared to Q1 FY 2024[7] - Net cash provided by operating activities was $2,309,000, a turnaround from a cash outflow of $244,000 in the prior year[17] - Accounts receivable increased by $967,000, up from $675,000 year-over-year, indicating higher sales or delayed collections[17] - Cash and cash equivalents at the end of the period were $13,864,000, compared to $7,024,000 at the end of the same period last year, reflecting improved liquidity[17] - The company experienced a net decrease in cash of $2,216,000, compared to a decrease of $348,000 in the prior year, highlighting cash flow challenges[17] - Expenditures for property and equipment were $37,000, down from $109,000, suggesting a more conservative investment approach[17] - The company reported a net cash used for investing activities of $58,000, a decrease from $133,000 in the previous year, indicating reduced capital expenditures[17] Shareholder Value and Compensation - The company repurchased common stock amounting to $4,536,000 during the period, indicating a strategy to return value to shareholders[17] - Share-based compensation expense rose to $697,000 from $371,000, reflecting increased employee compensation costs[17] Marketing and Leadership - The company launched a new marketing campaign called "Triple Down on Bronchiectasis," which has received positive feedback[3] - Electromed hired Peter Horwich as the new VP of Marketing to lead market development initiatives[3]

Financial Data and Key Metrics Changes - Total net revenue for Q4 2024 was $14.8 million, a 9% year-over-year increase from Q4 2023, with full-year revenues reaching $54.7 million, a 14% increase from fiscal year 2023 [4][20] - Operating income for Q4 was $2.3 million and $6.6 million for the full fiscal year, both record figures, indicating strong top-line growth and improved operating leverage [5][20] - Net income for fiscal 2024 was $5.2 million or $0.58 per diluted share, a 62.7% increase compared to $3.2 million or $0.36 per diluted share in fiscal 2023 [20] Business Line Data and Key Metrics Changes - Revenue from the direct homecare segment, which accounted for 90% of overall revenue, increased by $5.6 million or 12.6% to $49.5 million [16] - Hospital revenue rose by $0.5 million or 21.9% to $2.5 million, driven by increased sales representatives and demand for capital devices [16] - Other revenue surged by $0.4 million or 94.8% to $0.8 million, primarily due to increased international distributor purchases [17] Market Data and Key Metrics Changes - The introduction of SmartVest Clearway into the hospital market resulted in a 22% growth in this segment during fiscal 2024 [10] - The company expanded its sales team to 53 representatives by the end of the fiscal year, with plans to increase to 57 by year-end fiscal 2025 [7] Company Strategy and Development Direction - The company is focused on market development to raise awareness of bronchiectasis, with clinical teams participating in regional conferences to educate healthcare providers [8] - Investments in sales incentives and recruitment are aimed at improving sales performance, with expectations for homecare revenue per rep to increase to $900,000 to $1 million in fiscal 2025 [7][30] - The company aims to enhance operational efficiency through investments in ERP systems and fulfillment teams, contributing to zero back orders [13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in continued revenue growth and operating leverage, citing improvements in supply chain and reimbursement processes [22][23] - The CEO highlighted the cohesive team and upgraded talent as key factors driving the company's success and operational improvements [28] - Management remains cautious about potential competition from new drug developments for bronchiectasis, emphasizing the need for comprehensive care that includes their products [26] Other Important Information - Electromed was recognized as one of the fastest-growing public companies in Minnesota, reflecting its operational execution and growth focus [14] - The company has maintained a strong cash position of over $16 million and no debt, achieving a working capital of $36.5 million [20] Q&A Session Summary Question: Key levers for operating leverage in fiscal 2025 - Management noted improvements in distribution costs and reduced need for corresponding investments in the reimbursement team as key drivers for continued operating leverage [22][23] Question: Impact of Insmed's drug on the company - Management indicated that while the drug is focused on inflammation, it does not address all aspects of bronchiectasis care, suggesting it will be part of a broader treatment continuum [25][26] Question: Reflections on the first year and future opportunities - The CEO reflected positively on the first year, emphasizing team collaboration and the introduction of successful products as significant opportunities for growth [27][29] Question: Revenue trends and guidance - Management expects to continue driving double-digit growth and expanding operating leverage, consistent with past performance [31]

Electromed, Inc. Investor Presentation August 27, 2024 NYSE American: ELMD Innovation Leader in Airway Clearance Technologies Investor Presentation | 1 Forward Looking Statements Certain statements in this press release constitute forward-looking statements as defined in the US Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "potential," "should," "will," and simi ...

Revenue Growth - Homecare revenue increased by $5,558,000, or 12.6%, in fiscal 2024 compared to fiscal 2023, driven by more direct sales representatives and improved referral efficiencies [102]. - Hospital revenue rose by $455,000, or 21.9%, in fiscal 2024, attributed to increased sales representatives and higher demand for capital and disposable products [103]. - Total revenue for fiscal 2024 was $54,716,000, an increase of $6,649,000 or 13.8% from $48,067,000 in fiscal 2023 [102]. - Other revenue surged by $402,000, or 94.8%, in fiscal 2024, mainly due to increased international distributor purchases [105]. Profitability - Gross profit increased to $41,726,000, representing 76.3% of net revenues in fiscal 2024, up from $36,519,000 or 76.0% in fiscal 2023 [106]. - Net income for fiscal 2024 was $5,150,000, a 62.7% increase from $3,166,000 in fiscal 2023, driven by revenue growth and decreased professional fees [113]. Expenses - Selling, general and administrative expenses rose by $2,894,000, or 9.2%, to $34,489,000 in fiscal 2024 [106]. - SG&A payroll and compensation-related expenses increased by $2,885,000, or 14.0%, to $23,437,000 in fiscal 2024, reflecting higher compensation for sales and support personnel [107]. - Research and development expenses decreased by $260,000, or 28.4%, to $656,000 in fiscal 2024, primarily due to reduced costs associated with the SmartVest Clearway platform development [110]. Cash Flow and Investments - Cash flows from operating activities provided $9,067,000 in fiscal 2024, consisting of net income and various adjustments, despite decreases in accounts payable and accrued liabilities [114]. - Net cash used in investing activities was approximately $395,000 in fiscal 2024, including $287,000 for property and equipment expenditures [115]. - The company spent approximately $287,000 on property and equipment in fiscal 2024, significantly lower than $1,648,000 in fiscal 2023 [120]. - The company expects to finance planned equipment purchases through cash flows from operations or borrowings under the credit facility [120]. Financial Position - The company has approximately $36,496,000 in working capital, which is expected to meet liquidity needs for at least the next twelve months [117]. - The renewed credit facility provides a revolving line of credit with a maximum borrowing limit of $2,500,000, secured by a security interest in the company's assets [118]. - The company is subject to financial covenants under its credit facility, including a minimum tangible net worth of $10,125,000 [119]. Taxation - The effective tax rate for fiscal 2024 was 26.8%, up from 22.5% in fiscal 2023, influenced by state income taxes and R&D tax credits [113]. Future Plans - The company plans to expand its sales force by adding three territories and direct sales representatives to accelerate revenue growth in fiscal 2025 [91]. - The company experienced increased lead times and material costs in the supply chain during fiscal 2023, but expects a return to normal lead times in fiscal 2024 [92]. - Net interest income increased to approximately $455,000 in fiscal 2024 from $78,000 in fiscal 2023, primarily due to higher savings rates on increased cash balances [112].

Exhibit 99.1 Electromed, Inc. Announces Record Fiscal Year 2024 Financial Results Record Q4 and full year financial results NEW PRAGUE, Minn.--(BUSINESS WIRE)-- Electromed, Inc. ("Electromed") (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced financial results for the three months ("Q4 FY 2024") and full year ("FY 2024") ended June 30, 2024. Q4 FY 2024 Financial Highlights ● Net revenues increased 9.0% to a record $14.8 million in Q4 FY 2024, from $13.6 million in ...

Electromed, Inc. (NYSE:ELMD) Q3 2024 Earnings Conference Call May 7, 2024 5:00 PM ET Company Participants Mike Cavanaugh - IR James Cunniff - President, CEO & Director Bradley Nagel - CFO, Treasurer & Company Secretary Conference Call Participants Aaron Wukmir - Lake Street Capital Markets Operator Greetings, and welcome to the Electromed Third Quarter Fiscal 2024 Financial Results Conference Call. [Operator Instructions]. I would now like to turn the conference over to Mike Cavanaugh, Investor Relations. P ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No.: 001-34839 Electromed, Inc. (Exact Name of Registrant as Specified in its Charter) (State or other jurisdiction of incorporation or orga ...

"I am excited to announce another record revenue quarter in the third quarter of fiscal year 2024," said Jim Cunniff, President, and Chief Executive officer. "Our company continues to operate at a high level, further driving the adoption of our best-in-class product, backed by careful commercial expansion and excellent operational efficiency. Our strategy has again generated double-digit revenue growth, with significant operating leverage that is resulting in strong profitability. The team remains focused o ...

NEW PRAGUE, Minn.--(BUSINESS WIRE)--Electromed, Inc. (“Electromed” or the “Company”) (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced that Jim Cunniff, President and Chief Executive Officer, and Brad Nagel, Chief Financial Officer, are scheduled to attend the 2024 Sidoti March Small-Cap Virtual Conference on March 13-14, 2024. Electromed’s management team will present at 10:45 a.m. Eastern Time on Wednesday, March 13, 2024. A live and archived webcast of the even ...

ljubaphoto Electromed, Inc. (NYSE:ELMD) recently reported an impressive quarter, and noted beneficial expectations for the year 2024. With a total market opportunity of close to 4.2 million patients suffering from Bronchiectasis, I assumed that the total market opportunity could be around $8.4 billion. Given the current revenue line, there is significant room for improvement thanks to direct-to-consumer and medical marketing as well as internationalization efforts. If we also include the stock repurchas ...